EUVIMEDEUVIMED entdecken
Fallbericht

Glucocorticoid sparing effect on adalimumab for refractory pyoderma gangrenosum in patients with rheumatoid arthritis: A case series

Shin-Ichiro Ohmura iD, Naomi Morishita, Haruka Yonezawa, Toshitaka Yukishima, Yusuke Ohkubo

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxae075 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Shin-Ichiro Ohmura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan. Hauptthemen laut MEDLINE: Adalimumab, Arthritis, Rheumatoid, Pyoderma Gangrenosum, Antirheumatic Agents. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pyoderma gangrenosum (PG) is a rare chronic skin disease characterized by painful skin ulcers. There are no treatment guidelines for PG; however, systemic treatment is often administered. Recently, adalimumab (ADA), a fully human monoclonal antibody against tumour necrosis factor, was approved for the treatment of refractory PG in Japan. However, data are limited, and it is not clear whether ADA has the same effect on the treatment of PG in patients with systemic rheumatic disease (SRD), including rheumatoid arthritis (RA). In addition, the glucocorticoid-sparing effect of ADA in SRD patients with PG has not yet been clarified. Herein, we present two successful cases of RA with glucocorticoid-refractory PG on ADA treatment. Our report suggests that ADA may have a glucocorticoid-sparing effect on refractory PG in patients with RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabArthritis, RheumatoidPyoderma GangrenosumAntirheumatic AgentsGlucocorticoidsHumansFemaleMiddle AgedTreatment OutcomeMaleAgedAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Adalimumabglucocorticoidpyoderma gangrenosumrheumatoid arthritissystemic rheumatic disease

Substanzen

AdalimumabAntirheumatic AgentsGlucocorticoidsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Rheumatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.
  • Department of Dermatology, Seirei Hamamatsu General Hospital, Hamamatsu, Shizuoka, Japan.

ORCID-Profile: Shin-Ichiro Ohmura

Zitieren

APA

Ohmura, S. I., Morishita, N., Yonezawa, H., Yukishima, T., & Ohkubo, Y. (2025). Glucocorticoid sparing effect on adalimumab for refractory pyoderma gangrenosum in patients with rheumatoid arthritis: A case series. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxae075

Vancouver

Ohmura SI, Morishita N, Yonezawa H, Yukishima T, Ohkubo Y. Glucocorticoid sparing effect on adalimumab for refractory pyoderma gangrenosum in patients with rheumatoid arthritis: A case series. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxae075

BibTeX
@article{Ohmura2025,
  author = {Ohmura, Shin-Ichiro and Morishita, Naomi and Yonezawa, Haruka and Yukishima, Toshitaka and Ohkubo, Yusuke},
  title = {Glucocorticoid sparing effect on adalimumab for refractory pyoderma gangrenosum in patients with rheumatoid arthritis: A case series},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxae075}
}
Kostenlos starten →